CAR-NK cell therapy in AML: Current treatment, challenges, and advantage

• Published in: Biomedicine & pharmacotherapy Vol. 177; p. 117024
• Main Authors: Bahramloo, Mohammadmahdi, Shahabi, Sina Alinejad, Kalarestaghi, Hossein, Rafat, Ali, Mazloumi, Zeinab, Samimifar, Arian, Asl, Khadijeh Dizaji
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.08.2024; Elsevier
• Subjects: Acute Myeloid Leukemia; Animals; CAR NK cell therapy; Engineered cell therapy; Humans; Immunotherapy; Immunotherapy, Adoptive - methods; Killer Cells, Natural - immunology; Leukemia, Myeloid, Acute - immunology; Leukemia, Myeloid, Acute - therapy; Receptors, Chimeric Antigen - immunology; Engineered cell therapy; Acute Myeloid Leukemia; CAR NK cell therapy; Immunotherapy
• ISSN: 0753-3322; 1950-6007; 1950-6007
• DOI: 10.1016/j.biopha.2024.117024

Over the last decade, discovery of novel therapeutic method has been attention by the researchers and has changed the therapeutic perspective of hematological malignancies. Although NK cell play a pivotal role in the elimination of abnormal and cancerous cells, there are evidence that NK cell are disarm in hematological malignancy. Chimeric antigen receptor NK (CAR-NK) cell therapy, which includes the engineering of NK cells to detect tumor-specific antigens and, as a result, clear of cancerous cells, has created various clinical advantage for several human malignancies treatment. In the current review, we summarized NK cell dysfunction and CAR-NK cell based immunotherapy to treat AML patient.